Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
|Articles|January 28, 2022
Daily Medication Pearl: Umbralisib (Ukoniq)
Author(s)Saro Arakelians, PharmD
Umbralisib (Ukoniq) is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma.
Advertisement
Medication Pearl of the Day: Umbralisib (Ukoniq)
Indication: Umbralisib (Ukoniq) is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 1 prior anti-CD20-based regime and for adult patients with relapsed or refractory follicular lymphoma who have received at least 3 prior lines of systemic therapy.
Insight:
- Dosing: Recommended dosage 800 mg orally once daily with food.
- Dosage forms:Tablets 200 mg.
- Adverse events: The most common (≥15%) adverse reactions—including laboratory abnormalities—were increased creatinine, diarrhea-colitis, fatigue, nausea, neutropenia, transaminase elevation, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, decreased appetite, and rash.
- Mechanism of action: Umbralisib inhibits multiple kinases. In biochemical and cell-based assays, umbralisib inhibited PI3Kδ and casein kinase CK1ε. PI3Kδ is expressed in normal and malignant B-cells; CK1ε has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies.
- Manufacturer: TG Therapeutics
Sources:
Advertisement
Related to this article
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
Study shows prior authorization and high out-of-pocket costs drive prescription abandonment, limiting Medicare Part D blood cancer treatment access to oral anticancer medications.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
Persistent symptoms can complicate life after a multiple myeloma treatment response, making routine symptom assessment and targeted supportive care essential.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Over Half of RSV-Related Deaths in Hospitalized Adults Occur After Discharge
2
Caitlin McClain, Peggy Lillis Foundation Board Member, Shares Her Experience With C difficile
3
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5